Go Back   ManagementParadise.com | Management & Business Education Learning Platform PUBLISH / UPLOAD PROJECT OR DOWNLOAD REFERENCE PROJECT > Financial Management

Financial Analysis of Medimix International

Discuss Financial Analysis of Medimix International within the Financial Management forums, part of the PUBLISH / UPLOAD PROJECT OR DOWNLOAD REFERENCE PROJECT category; Medimix International is a global online-based market research company headquartered in Miami, Florida. The company was founded in 1989 in ...

Reply

 

Thread Tools Display Modes
Financial Analysis of Medimix International
Old
 (1 (permalink))
Netra Shetty
netrashetty is on a distinguished road
 
netrashetty
Student of PGDM at Mats Institute of Management and Entrepreneurship
Bangalore, Karnataka
Management Paradise Guru
 
Status: Offline
Posts: 4,857
Join Date: Dec 2010
Location: Bangalore, Karnataka
Financial Analysis of Medimix International - February 12th, 2011

Medimix International is a global online-based market research company headquartered in Miami, Florida. The company was founded in 1989 in France, and moved its global headquarters to the United States in 2002. Medimix International is one of the pioneers in online marketing research for the lifescience industries, and has developed a proprietary panel of health care professionals since 1995.
Medimix International is a member of the American Marketing Association (AMA), European Pharmaceutical Market Research Association (EphMRA), Pharmaceutical Business Intelligence Research Group (PBIRG), Pharmaceutical Marketing Research Group (PMRG) and the European Society for Opinion & Marketing Research (ESOMAR).


Medarex (NASDAQ:MEDX) is a young biotech company that makes human monoclonal antibodies (mAb), which mimic the action of the immune system and can be more effective and less toxic than traditional drugs. Medarex has always operated at a loss, but its leading compound, a mAb cancer drug called ipilimumab, has the potential to be a major driver of revenue for the company if successful. Jointly being developed with Bristol-Myers Squibb, ipilimumab is currently in Phase III clinical trials for metastatic melanoma and the FDA has expedited its clinical testing and approval, but may also be effective for other types of cancers.[1]

Medarex owns the UltiMAb process that uses transgenic mice to produce fully human antibodies for medical purposes, and licenses this technology to other pharmaceutical and biotech companies.[2] The company has more than 35 partnerships with external companies including Johnson & Johnson and Pfizer.[3]

Overview

Medarex (MEDX) is a biopharmaceutical company focused on the development of antibodies in oncology and immunologic diseases. It was founded in 1987 and its IPO on the New York Stock Exchange took place in 1991. [4]

Antibodies are an increasingly important tool in the arsenal of advanced "targeted therapies" that pharmaceutical companies are rolling out to combat diseases such as cancer. Traditional cancer drugs kill cancer cells, but also healthy cells as well, making them extremely toxic and limits the doses that can be given to patients. Targeted therapies only impact cancerous cells and can be given in higher doses, and are often more effective than traditional chemotherapy regimens. Examples include Genentech's Avastin, Herceptin, and Lucentis and Medimmune's Synagis.

Contents
1 Overview
2 Trends & Forces
2.1 Uncertainty over lead compound Ipilimumab
2.2 Growth in the Oncology Market Boosts MEDX's Revenues
3 Competition
4 References
It is relatively easy for a biotech company to make a mouse or chicken antibody.[5] However, these animal antibodies can cause severe immune system reactions when used in humans. As a result, human or human-like antibodies are preferred, but are also harder to produce.

Over 40 antibodies derived from MEDX's technology are currently in human clinical testing, with 7 of the most advanced product candidates presently in Phase 3 clinical trials.[6] Several of these products were developed in-house while others were developed by MEDX's partners.

Currently, revenues are only derived from licensing agreements and royalties, but if MEDX successfully launch a drug, its sales will increase very quickly.



2007 revenues were $56 million, a 16% increase from 2006.[7] Medarex has been operating at a loss as it has yet to see the launch of a major drug. In 2007, the net loss was $27 million, down from $181 million in 2006 due to a one-time gain from the sale of its interest in Genmab of $152 million.[8]



MEDX research and development expenditures has been rising steadily over the years. Its R&D costs rose 40% from 2005 to 2006, due to the expensive clinical trials that the company has to conduct as it seeks FDA approval for its drugs. [9]

MEDX makes the UltiMAb Human Antibody Development System used to create human antibodies which are better than its competitors. By producing fully human antibodies, there is no need for time-consuming and expensive humanization, which means changing a non-human antibody to be more human-like. These fully-human antibodies also exhibit a much greater binding affinity for their molecular targets than their non-human counterparts, resulting in increased drug efficacy.[10]

Trends & Forces

Uncertainty over lead compound Ipilimumab
Ipilimumab is MEDX's lead compund and is currently in Phase III clinical trials for metastatic melanoma (a type of skin cancer). Ipilimumab is likely to be the biggest contributor to revenue growth and is forecast to reach sales of $112 million in 2010.[11] Ipilimumab is jointly developed with Bristol-Myers Squibb Company (BMY).

In Phase II clinical trials, 11.4%, or 4 of 35 patients, were still alive after 4 years, and the median overall survival for patients treated with ipilimumab in combination with dacarbazine was 15 months in this study. These results compare favorably to median overall survival ranges of 6 to 9 months for patients with treated or previously untreated advanced melanoma treated with standard chemotherapy. [12]


Growth in the Oncology Market Boosts MEDX's Revenues
According to reports by MarketResearch, the oncology market forecasts show an increase from $33billion in 2004 to over $89.5billion in 2012.[13] Factors like an aging population and an increased understanding of the genetics of cancer are fueling this growth. Medarex’s lead compound is targeted for melanoma and possibly other types of cancer and sales will benefit from this trend. [14]

Competition

In the metastatic melanoma market, the following drugs are currently being used to treat metastatic melanoma:

Dacarbazine: This is a generic drug and is widely used in first-line therapy. As an alkylating agent, it hinders DNA replication in both cancerous and healthy cells. [15]
Fotemustine: It is sold as Muphoran and is marketed by Servier, a French pharmaceutical company. Fotemustine is in the same drug class as Dacarbazine and has similar effects.
There are limited treatment options for metastatic melanoma and the prognosis for patients is poor. Ipilimumab would be more effective and less toxic than currently available treatments.[16]

More than 24 companies claim ownership of technology for generating human or humanized antibodies. These include:

Genmab: It is a publicly listed company listed on the OMX Nordic Exchange in Coopenhagen. Genmab has developed UniBody, a proprietary technology which is used to create a smaller antibody format which may offer several advantages over traditional full size monoclonal antibodies. MEDX has an approximately 5.1% interest in Genmab.
Regeneron Pharmaceuticals (REGN) : REGN currently has 1 marketed product and 3 drugs in its pipeline. It also has a genetically engineered mouse model (VelocImmune) which is used to produced humanized antibodies.[17]
Alexion Pharmaceuticals (ALXN): Alexion creates many variations of human and human-like antibodies and screens those as possible drug candidates. [18]
Dyax (DYAX): Dyax’s makes test products that rapidly identify compounds that bind with very high affinity and specificity to therapeutic targets. [19] The company also has three drugs under development in its pipeline.
XOMA (XOMA): XOMA's Human Engineering(HE) technology is a clinically-tested humanization method for reducing the negative immune reactions that non-human antibodies cause, while retaining the efficacy of the antibody. [20] It also has 7 drugs under development in its pipeline.
PDL BioPharma (PDLI): PDLI has a proprietary antibody humanization technology that has been used to develop successful antibodies such as Herceptin and Avastin. However, companies have generally switched to technologies that produce fully human antibodies instead of merely humanized ones.
In millions of USD Medarex Regeneron Alexion Dyax Xoma PDLI
Total Revenue 56.26 125.02 72.04 26.1 84.25 258.93
Gross Profit 35.91 -76.59 65.34 26.1 84.25 258.93
Net Income -27.07 -105.6 -92.29 -56.31 -12.33 -21.06
Return on Average Assets -3.16% -13.88% -27.64% -65.56% -14.10% -1.66%
Return on Average Equity -4.99% -31.20% -81.59% -212.66% NA -3.98%
Employees 500 682 434 177 311 887
Advertisements

Friends: (0)
Reply With Quote
Reply

Bookmarks

Tags
accounting analysis, annual statement, balance sheet, business finance, business valuation, debt instruments, finance companies, financial analysis, financial analysis report, financial analysts, financial ratio, financial statement, fundamental analysis, funds management, hedge funds, income statement, medimix international, mutual funds, net income, p&l account, personal finance, private equity, public finance, return on equity, us company finance
Related to Financial Analysis of Medimix International
 

Similar Threads

Thread Thread Starter Forum Replies Last Post
Customer Relationship Management of Medimix International Anjali Khurana Marketing Management 1 August 22nd, 2017 04:35 PM
Human Resource Management of Medimix International Netra Shetty Human Resources Management (H.R) 1 March 28th, 2016 04:20 PM
Financial Analysis of Brinker International Netra Shetty Financial Management 0 February 10th, 2011 02:39 PM
Organisational Structure of Medimix International Netra Shetty Human Resources Management (H.R) 0 February 5th, 2011 11:04 AM
SWOT ANALYSIS ON Medimix International Abhijeet S Principles of Management ( P.O.M) 0 November 30th, 2010 02:55 PM
 


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On
Trackbacks are On
Pingbacks are On
Refbacks are Off


ManagementParadise.com is not responsible for the views and opinion of the posters. The posters and only posters shall be liable for any copyright infringement.



Search Engine Optimization by vBSEO ©2011, Crawlability, Inc.